Skip to content

Immatics

US · IMTX #3173 by market cap Listed 2018
7.45 -0.05 -0.67%
Live - 5344 symbols - heartbeat 201s ago · 2026-10-08 05:54
Pre-market 7.40 -0.67%
After-hours 7.88 +5.77%
Overnight 7.46 +0.13%
Market cap
1.11B
P/B
2.49
EPS
-1.80
Reader sentiment Are you bullish or bearish on IMTX?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 2.49 Cheap vs history 27th percentile
5-year average 4.95 · #262 of 513 in Biotechnology
P/E ratio -4.19 Expensive vs history 73rd percentile
5-year average -1.77 · forward -3.52
P/S ratio 23.86 Expensive vs history 90th percentile
5-year average 12.08 · forward 30.65 · #219 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Immatics (IMTX) 1.11B -4.19 2.49 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value7.59 Economic moatNone UncertaintyVery High

Trading 1.9% below Morningstar's fair value estimate.

Fair value

Immatics NV receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% discount to our quantitative fair value estimate of $7.59 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet increases our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 7.5, which lies in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 5.0%, for example, falls in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-10-08 05:54:03 · For reference only, not investment advice and not tailored to your situation.